Mezlocillin pharmacokinetics in patients with normal and impaired renal functions.

Antimicrobial Agents and Chemotherapy
T BerganE Wiik-Larsen

Abstract

The pharmacokinetics of intravenous bolus doses of 1.0 g of mezlocillin were studied in 13 persons with normal and reduced renal functions. In renal failure a moderate increase was observed for the terminal serum half-life(t1/2 beta). This changed from a mean of 1.1 h at a glomerular filtration rate of 100 ml/min to 1.6 h at 10 ml/min. The difference was not statistically significant. The excretion of unchanged drug in urine during 24 h was reduced from a mean of 59.4% (range, 52 to 77) in subjects with glomerular filtration rate above 50 ml/min to 10% (range, 7.9 to 12.1) in two patients with glomerular filtration rate of 10 to 20 ml/min. The volume of distribution during the beta-phase, Vd,b, was 14% of the body weight. Much of the antibiotic was metabolized, and this proportion increased upon reduction in renal function.

References

Feb 1, 1978·Antimicrobial Agents and Chemotherapy·B F IssellS Weaver
Jul 1, 1978·Clinical Pharmacology and Therapeutics·S J Pancoast, H C Neu
Sep 1, 1978·Antimicrobial Agents and Chemotherapy·P Fiegel, K Becker
Dec 1, 1978·Antimicrobial Agents and Chemotherapy·T Bergan
Jan 1, 1971·Acta Medica Scandinavica·T BerganA Oyri

❮ Previous
Next ❯

Citations

Jan 1, 1982·European Journal of Clinical Pharmacology·G R AronoffN S Fineberg
May 1, 1988·Zentralblatt Für Bakteriologie, Mikrobiologie, Und Hygiene. Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology·J KnöllerW König
Apr 1, 1980·Antimicrobial Agents and Chemotherapy·N Frimodt-MöllerP O Madsen
Aug 1, 1981·Antimicrobial Agents and Chemotherapy·P C FuchsE H Gerlack
Sep 1, 1981·Antimicrobial Agents and Chemotherapy·K J LavelleG R Aronoff
Jan 1, 1984·Antimicrobial Agents and Chemotherapy·W G KramerL S Frankel
Mar 1, 1982·Antimicrobial Agents and Chemotherapy·A MangioneW J Jusko
Nov 1, 1982·Pharmacotherapy·R V McCloskeyG R Aronoff
Apr 1, 1985·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·P A Levine

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.